Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial
| Autor: | F, Stölzel, M, Pfirrmann, W E, Aulitzky, M, Kaufmann, H, Bodenstein, M, Bornhäuser, C, Röllig, M, Kramer, B, Mohr, U, Oelschlägel, N, Schmitz, S, Soucek, C, Thiede, G, Ehninger, M, Schaich, H, Rueckle-Lanz |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Risk Oncology Cancer Research medicine.medical_specialty Poor prognosis Scoring system Prognostic score Internal medicine Overall survival Humans Medicine Mutational status Secondary Acute Myeloid Leukemia Prospective Studies Aged Aged 80 and over Clinical Trials as Topic Platelet Count business.industry Nuclear Proteins Neoplasms Second Primary Hematology Middle Aged Prognosis Surgery Leukemia Myeloid Acute Logistic Models Treatment Outcome Mutation Risk stratification Cohort Female business Nucleophosmin |
| Zdroj: | Leukemia. 25:420-428 |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | Patients with secondary acute myeloid leukemia (sAML) are generally thought to have a poor prognosis. As there are no prognostic risk stratification models for patients with sAML available, the aim of this study was to obtain a scoring system. Prognostic factors influencing overall survival (OS) and event-free survival (EFS) were analyzed in 305 sAML patients treated in the prospective AML96 trial. The obtained prognostic scoring system was then validated in an independent patient cohort included in the AML2003 and AML60+ trials. In addition to the known risk factors for AML, age and karyotype, we identified the absolute platelet count and the Nucleophosmin 1 mutational status at diagnosis as prognostic factors of sAML patients. A pronounced distribution of sAML patients into three score groups was achieved showing a 2-year OS/EFS of 52/44% for patients in the low-risk group, 21/12% in the intermediate-risk group and 7/3% in the high-risk group (both P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|